Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4% S 0.160 +3.2% OMI 0.315 +0.0% BMM 4.02 +5.8% CGD 0.630 +10.5% OCG 0.275 −1.8% CAMB 0.990 −1.0% HMR 0.600 −3.2% GOFL 0.025 +0.0% SIG 1.01 −1.9% SGQ 0.300 +0.0% AMCO 0.220 −12.0% TRS 0.055 +0.0% RRI 0.265 +0.0% GAL 0.390 −2.5% LIB 0.800 −12.1% SMY 0.290 +23.4%
Earnings

Light AI reports Financial Results for Three Months and Year ended December 31, 2025

By The Northwire Desk — AI Analysis Mar 26, 2026 · 23:46 ALGO · 0.09 LIGHT AI INC.
ALGO · Price

Executive Summary

  • Light AI Inc. released its Q4 2025 and full‑year 2025 financial and operating results.
  • Total operating expenses fell to $2.3 M for the quarter (down from $5.6 M in the prior quarter) but rose to $4.3 M for the year, reflecting higher marketing and product development costs after going public.
  • Cash decreased to $6.5 M at year‑end 2025, with adjusted working capital of $5.45 M; the company previously raised $1.52 M in a unit offering on Jan 8 2025.

Key Details

  • Quarterly Operating Expenses: $2.3 M for Q4 2025 vs. $5.6 M in Q3 2025 and $2.4 M in Q4 2024.
  • Annual Operating Expenses: $4.3 M for 2025 vs. $8.1 M in 2024.
  • Cash Position: $6.5 M as of Dec 31 2025 (down from $15.2 M on Dec 31 2024).
  • Total Assets: $6.9 M at year‑end 2025 (down from $17.1 M at year‑end 2024).
  • Adjusted Working Capital: $5.45 M as of Dec 31 2025 vs. $14.64 M on Dec 31 2024.
  • Financing Activity: On Jan 8 2025, closed second tranche of offering – 2,757,000 units at $0.55 per unit, gross proceeds $1,516,350.
  • Clinical/Regulatory Status: Still in clinical trial and regulatory phase; expects commercialization in Q3‑Q4 2026 pending approvals.
  • CEO Quote: “Light AI has reached a key inflection point with the completion of its first commercially ready QuickScan™ Strep A application…” – John R. Luna, CEO.

Notable Quotes

"We are executing on a dual-track strategy both advancing clinical trials while advancing regulatory approvals to be ready to pursue multiple commercialization opportunities…" – John R. Luna, Chief Executive Officer.

Read the original news release →

More from LIGHT AI INC.

Jun 29, 2026 · 07:00

Pre-revenue AI diagnostics developer advances regulatory clearance for smartphone-based Strep A detection amid persistent cash burn and dilution risk.

Production / Operations Jun 22, 2026 · 18:41

Pre-revenue AI diagnostics company closes dilutive financing to fund regulatory milestones amid going concern risks.

Financings Jun 19, 2026 · 18:00

Light AI Announces Closing of C$5,000,000 Secured Convertible Debenture Unit Financing

Financings Jun 15, 2026 · 18:25

Light AI pilots Strep A diagnostic in NZ as FDA pivotal trial launches, but pre-revenue status and going concern risk persist.

Production / Operations Jun 04, 2026 · 07:00

Light AI Advances FDA Pivotal Trial for Strep A AI Diagnostic Amid Cash Burn and Dilutive Financing

Regulatory May 21, 2026 · 07:15

Light AI’s C$5 Million Lifeline Comes With Dilutive Terms and Board Strings as Cash Burn Intensifies

Financings